http://www.lisbonaddictions.eu/start...23-25 septembre 2015... BIG DATA...

The First European conference on addictive behaviours and dependencies will be held in Lisbon on 23–25 September 2015.

Sur la protection de la jeunesse, la négligence ou le manquement grave.

Où sont les Français? Car les choses se transportent au travers des autoroutes Françaises. Et Interpol est à Lyon. La Justice internationale étant située à La Haye auX Pays-Bas.

http://www.coe.int/t/dg3/pompidou/default_en.asp, à Strasbourg.

Council of Europe,
Avenue de l'Europe F-67075 Strasbourg Cedex -
Tel. +33 (0)3 88 41 20 00

On y était, on y revient.

Avec car le monde médical n'est pas loin, l'industrie non plus, ses lobbies partout:

http://www.imi.europa.eu/content/mission

http://ec.europa.eu/programmes/horizon2020

Sur le vieillissement de la population, car il ne faut pas oublier les séniors:

http://ec.europa.eu/programmes/horizon2020/en/news/rheumatology-aging-conference-2015

"The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations)." (Bron: http://www.imi.europa.eu/content/mission)

http://www.imi.europa.eu/events/2015/03/13/imi-stakeholder-forum-2015:

[...]

Session 3B│Enabling technologies: better health outcomes through big data
This session represents a key element in a broader consultation on a planned IMI programme on ‘better health outcomes through big data'. The programme is outlined in this consultation paper . IMI is keen to discuss the proposed programme with all stakeholders, particularly payers, regulators, prescribers, patients and HTAs.

[...]

P.s: Sur les produits mis sur le marché européen.

"Ritaline-rapport-accablant-de-la-Commission-nationale-des-stupefiants-et-des-psychotropes", les remarques sont les bienvenues.